Background: Autologous chondrocyte implantation (ACI) is used worldwide in the treatment of cartilage defects in the knee. Several demographic and injury-specific risk factors have been identified that can affect the success of ACI treatment. However, the discovery of predictive biomarkers in this field has thus far been overlooked.
therapies for cartilage repair. There is, therefore, a clinical and financial need for reproducible preoperative biomarker assays, to be used in conjunction with known demographic risk factors, to help the clinician decide if a patient should be considered suitable for treatment using these interventions.
Wet biomarkers derived from body fluids (eg, synovial fluid and blood plasma) represent an attractive option for the preoperative screening of patients. In addition, such markers could also enable longitudinal analyses to monitor treatment outcomes, act as surrogate outcomes, or help to elucidate the reasons why some patients benefit from treatments when others fail to do so. Finally, the characterization of specific biochemical and/or cellular changes in these fluids, associated with treatment failure or success, may help to identify markers to target and improve the therapeutic effect. 16 Several compounds found in the blood and synovial fluid have been associated with cartilage injuries and OA progression, including matrix molecules and enzymes associated with cartilage degradation such as hyaluronan (HA), 37 cartilage oligomeric matrix protein (COMP), 7 chondroitin sulfate (CS), 3 aggrecanase-1/aggrecanase-2 (ADAMTS-4/ADAMTS-5), 17, 23, 46 and matrix metalloproteinases (MMPs). 1 In addition, other molecules may be suitable as biomarkers such as those associated with inflammation, including soluble CD14 (sCD14). 11, 26 The main objective of this study was to begin the process of establishing a reliable panel of biochemical markers that could be used in the preoperative setting to optimize treatment selection for cartilage defects.
METHODS Patients
After approval from the Black Country National Research Ethics Service committee (06/Q2601/9) and with informed consent, synovial fluid and plasma were obtained before cell implantation from all consenting patients treated with ACI at our center from 2007 to 2012 inclusive. ACI is a 2-stage procedure, with arthroscopic cartilage harvest at stage 1 and cells being implanted during arthrotomy at stage 2. The procedure was performed using cultureexpanded chondrocytes, as described previously. 4, 6, 32 The indication for ACI in all of the patients included in this study was the presence of a focal cartilage defect in the knee. All patients included in the study had undergone either debridement or microfracture as a previous surgical treatment for these defects, and as such, none of the patients could be described as acutely injured. At baseline (before ACI), we recorded age, sex, BMI, and functional status as characterized by the modified Lysholm scale (score range of 0-100, where the maximum score is 100, which denotes an ''excellent'' functioning knee joint). 38 We further recorded the defect location and size, whether the defect was ''bone on bone,'' and whether the patient underwent additional procedures including ligament reconstruction, meniscal replacement surgery, or osteotomy. We also recorded the type of material used to cover the defect before cell implantation, that is, autologous periosteum or porcine collagen membrane (Chondro-Gide; Geistlich). A patient was described as a responder or a nonresponder based on the change in the 1-year postoperative Lysholm score. Responders were patients who had improved by at least 10 points, which is comparable with the published minimum clinically important difference for 100-point functional knee scores reported in other studies. 14, 34, 36 Synovial Fluid and Plasma Collection and Storage
To collect synovial fluid, patients' knee joints were injected with 20 mL of saline, followed by 20 cycles of extension and flexion before intra-articular aspiration. We have been collecting synovial fluid from knee joints for biomarker analyses for the last 15 years. This process of collection has been optimized for the ease of synovial fluid volume retrieval by the clinician and to ensure, as much as possible, consistency between samples. Blood plasma was obtained by venipuncture at the time of ACI. Synovial fluid and blood were centrifuged at 600g for 15 minutes at 4°C. Synovial fluid and blood plasma were then divided into aliquots and stored in liquid nitrogen before biomarker analyses. The dilution of synovial fluid was accounted for by normalizing synovial fluid biomarker values to the urea concentration in blood plasma. In brief, urea concentrations were measured in synovial fluid and in blood plasma (which were harvested at the same time), and a dilution factor was calculated for synovial fluid based on the assumption that the urea concentration is equivalent in plasma and synovial fluid, which is a previously reported methodology. 21 COMP, HA, sCD14 levels, and ADAMTS-4 activity in synovial fluid were calculated by multiplying assay-derived concentrations by the dilution factors obtained from the urea analyses (QuantiChrom Urea Assay Kit, Universal Biologicals).
COMP and HA Quantification in Synovial Fluid and Matched Blood Plasma
COMP levels in synovial fluid and plasma were determined using an enzyme-linked immunosorbent assay (ELISA) (BioVendor Laboratory Medicine). For calculations of the COMP concentration, the logit log function was used to linearize standard curves. HA levels in synovial fluid and plasma were measured using an enzyme-linked protein binding assay (Corgenix). Third-order polynomial regression was used to generate the best-fit curve to calculate the concentration of HA in patient samples. For COMP and HA assays, all commercially provided quality controls were within accepted limits. The limit of detection (LoD) for COMP and HA were calculated to be 0.1 ng/mL and 17.8 ng/mL, respectively. The interassay and intra-assay coefficients of variance were 7.1% and 1.6% for COMP assays and 19.1% and 4.5% for HA assays, respectively.
sCD14 Quantification in Synovial Fluid sCD14 was measured in synovial fluid samples using the Human sCD14 Quantikine ELISA Kit (R&D Systems). For calculations of sCD14 concentration, the logit log function was used to linearize standard curves. The LoD was calculated to be 141 pg/mL. The interassay and intra-assay coefficients of variance were 9.0% and 4.3%, respectively.
ADAMTS-4 Activity Quantification in Synovial Fluid
An endpoint fluorometric substrate assay (SensoLyte 520 Aggrecanase-1 Assay Kit; AnaSpec) was used to measure ADAMTS-4 activity in synovial fluid samples. The kit contains an internally quenched 5-carboxyfluorescein/tetramethylrhodamine fluorescence resonance energy transfer (FRET) substrate, which is optimized to specifically detect ADAMTS-4 activity (down to 4 ng/mL). For calculations of ADAMTS-4 activity, linear standard curves were constructed by plotting relative fluorescence units versus the concentration of ADAMTS-4 standards (AnaSpec). The LoD was calculated to be 1.4 ng/mL, with interassay and intra-assay coefficients of variance being 12.3% and 1.7%, respectively.
Statistical Analysis
The distributions of all continuous variables were investigated using quantile-quantile (QQ) plots. These showed that age, BMI, and Lysholm scores followed a normal distribution, whereas defect area and levels of all biomarkers followed a log-normal distribution.
Some biomarker levels were below the assay detection limit (''nondetects'' or ''censoring''); in those cases, imputed biomarker levels were used that minimized bias. 29 The imputation was based on a larger set of biomarker samples, comprising all samples from the current study augmented with 66 samples from 54 patients collected at least 1 year postoperatively. When fewer than 10% of the specimens were a nondetect for a specific biomarker, an imputation value of (1/O2) times the LoD was used. At nondetect levels above 10%, we imputed using the expected value of the biomarker level. These values were calculated using a censored log-normal distribution through all biomarker levels above the detection limit. 28 However, no imputation was needed for such a biomarker when it was the dependent variable in the analysis; instead, we used a censored regression analysis. 12 For patients with 2 baseline specimens, that is, a stage 1 and a matched stage 2 sample, the mean biomarker level of both was used.
To find predictors of the postoperative functional status, a univariable linear regression analysis was performed using the postoperative Lysholm score as the dependent variable and including the baseline Lysholm score as a covariate. Independent variables were patient age at the time of ACI, BMI, defect location, defect area, having a bone-onbone defect, type of defect patch (periosteum or collagen), requirement of an extra procedure, and baseline level of the 4 synovial fluid biomarkers (HA, ADAMTS-4, COMP, and sCD14) and the 2 plasma biomarkers (HA and COMP). A multivariable linear regression analysis was then performed based on all predictors with a univariable P value \.15. Further univariable and multivariable linear regression analyses were performed to identify predictors of ACI outcomes based on the responder definition described above, namely, assuming that responders were patients with an improvement of at least 10 points. 14, 34, 36 These analyses were performed as logistic regression analyses, following the same methodology as outlined above for the linear regression analyses. The resulting model was then internally validated (see the Appendix, available in the online version of this article). For those biomarkers that were identified as having a predictive value, we also plotted their baseline levels versus the difference from the baseline Lysholm score to determine whether merely the presence of the biomarker or the quantity measured is important for predicting a response. This was examined further in a 2-way contingency table analysis (Fisher exact test). Finally, for all biomarkers with a P value in the multivariable linear or logistic regression analysis \.15, further linear regression analyses were performed to determine predictors of the biomarker levels among the other variables examined, that is, all demographic and defect characteristics as well as the levels of the other biomarkers in the same fluid compartment (synovial fluid or plasma). All regression analyses were performed using R version 3.0.3 (R Foundation for Statistical Computing) with the packages EnvStats, distrEx, rms, and lme4. All analyses used the appropriate transformation identified from the QQ plots, and a P value \.05 was assumed to denote statistical significance.
RESULTS

Patients
Fifty-four patients undergoing ACI were included in this study with a mean baseline Lysholm score of 47.4 6 17.0, which improved to 64.6 6 21.7 postoperatively (at a mean 2.2 6 3.0 years after treatment). Seventy-seven percent of patients showed an increase in the Lysholm score at this time point, with 59% improving at least 10 points; these were classed as responders in subsequent analyses. The study comprised samples from 38 male and 16 female patients aged between 17 and 61 years at the time of ACI. An overview of the demographic variables and defect characteristics analyzed is provided in Table 1 .
Biomarker Levels
From the 54 patients included, 76 samples were collected: 47 at stage 1 (before cartilage harvest) and 29 at stage 2 (before cell implantation 3-4 weeks later). In 11 patients, a sample was collected at both stages. The mean synovial fluid dilution factor (calculated using blood plasma urea content) 21 was 4.7 6 3.6, and in the responder and nonresponder groups, the mean dilution factor was 4.4 6 3.1 and 4.9 6 3.7, respectively. For 2 biomarkers (sCD14 and ADAMTS-4), we found samples with undetectable levels. To use the biomarker variables with these nondetects as predictors in a regression analysis, imputed values were used for all nondetect cases. For sCD14 levels, where sCD14 was below the detection limit in only 1 sample, the imputed value was taken equal to (1/O2) times the LoD of 0.14 ng/mL (0.10 ng/mL). The ADAMTS-4 determinations had 71% of nondetects, and its lower detection The American Journal of Sports Medicine limit (LDL) was 3.7 ng/mL. A censored log-normal distribution was fitted to the ADAMTS-4 data, giving a mean of 21.6 6 4.4. The expected value of ADAMTS-4 under the log-normal distribution and the condition that the value was below 3.7 ng/mL was 0.40 ng/mL. This value of 0.40 was used to impute the nondetect cases. Mean baseline biomarker levels after imputation are summarized in Table 1 .
Regression Analyses of Predictors of the Postoperative Lysholm Score After ACI
When using the postoperative Lysholm score as the main outcome, and including the baseline Lysholm score as a covariate, univariable linear regression models found 2 variables potentially associated with better outcomes, namely, lower age and lower ADAMTS-4 activity ( Table  2) . A higher baseline Lysholm score, lower age, and lower ADAMTS-4 activity all proved to be significantly associated with a higher 1-year Lysholm score in multivariable regression analysis (Table 3) .
Regression Analyses of Predictors of a 10-Point Improvement in the Lysholm Score After ACI (Responder Analysis)
Among our 54 patients, 32 had an improved Lysholm score (at least 10 points) after 1 year and were classed as responders, whereas 22 did not show such an improvement and were classed as nonresponders. Univariable logistic regression analyses found that lower age, collagen patch type, and lower ADAMTS-4 activity in synovial fluid predicted a positive response (Table 4) . A multivariable logistic regression model of potential predictors demonstrated that age, patch type, and ADAMTS-4 level were again predictive (Table 5 and Figure 1) .
Plotting baseline ADAMTS-4 levels versus the change in the Lysholm score from the baseline score suggested that the main predictive aspect of ADAMTS-4 was its presence rather than its quantity (data not shown). A simple 2-way contingency table analysis confirmed that this was indeed the case (P = .05, Fisher exact test) ( Table 6 ). The odds ratio of 0.33 indicates that when ADAMTS-4 activity The values for nondetects were imputed when calculating median biomarker levels.
was detectable, the odds of being a responder were 3 times smaller than when ADAMTS-4 activity was not detectable.
Predictors of ADAMTS-4 Activity
Finally, using a censored regression model (Table 7) , we found that none of the demographic or clinical baseline parameters were predictive of ADAMTS-4 activity; only higher sCD14 levels in synovial fluid were significantly associated with ADAMTS-4 activity (P = .01).
DISCUSSION
The overarching aim of this study was to begin the process of developing a panel of biomarkers that could help clinicians to successfully treat more patients at an early stage of joint damage with less invasive treatments, thereby reducing the number of patients who might otherwise progress to endstage OA and require knee replacement. 10, 12 To this end, we have attempted to derive a clinical prediction model by performing a series of univariable and multivariable linear and logistic regression analyses to predict clinical outcomes of ACI from biomarker levels and demographic variables. Important criteria in such models are the precision of regression coefficients and the ability to perform well over a broad range of samples. The emphasis on precision implies that hypothesis testing is less relevant, and as a consequence, no type I error adjustment was needed despite considering multiple independent variables. 40 Ultimately, our model requires validating with a further sample of patients. The internal validation that we performed (see Appendix) is a second-best option, but its results do suggest that our prediction model will indeed perform well with future samples. When using the postoperative Lysholm score as the outcome, and including the baseline Lysholm score as a covariate, lower age at ACI and lower ADAMTS-4 activity level were identified as promising predictors of better outcomes, and both proved significant in a multivariable analysis. When an improvement in the Lysholm score of at least 10 points was the definition of an ACI responder, which is an accepted clinical threshold in other published studies, 14, 34, 36 3 potential predictors were identified, namely, lower age, patch type used in the second stage of the procedure, and absence of ADAMTS-4 activity in synovial fluid. It is not too surprising that age at ACI and patch type have been identified in these analyses as potential predictors of ACI success in the clinic. Our group and others have already indicated that age and patch type have predictive value for ACI in terms of outcomes and the quality of repair cartilage, respectively. 13, 18, 20, 25, 31 However, the fact that we have identified ADAMTS-4 activity in synovial fluid as a potential predictive indicator for ACI is completely novel. It is known that ADAMTS-4 activity is elevated in the synovial fluid of arthritic joints. 23, 46 Together with ADAMTS-5 (another member of the ADAMTS gene family), ADAMTS-4 has been shown to accelerate the loss of aggrecan from cartilage, which is a major contributing factor in the progression of OA. 2, 35, 39 An alternatively spliced variant of the enzyme (ADAMTS-4_v1), which lacks the spacer domain and to date has only been found to be produced by OA synovium cells, is suggested to contribute similarly to the loss of aggrecan from the superficial zone of OA cartilage. 43, 44 Elevated ADAMTS-4 activity in the synovial fluid of patients who have poorer outcomes after ACI might therefore suggest that OA has already progressed too far, meaning that their joints are less likely to benefit from standard ACI treatment. Interestingly, we have also shown that none of the patient demographic or injury-associated variables examined in this study could help to predict ADAMTS-4 activity. Hence, ADAMTS-4 activity is an independent predictor of the postoperative Lysholm score. Previous work that was conducted on a larger cohort of patients, which included a proportion with end-stage OA, 33 also investigated the relationship between demographic variables and ADAMTS-4. The partial R 2 is a measure of the correlation of each variable with the postoperative Lysholm score while eliminating the influence of the baseline Lysholm score.
That study found significantly higher levels of ADAMTS-4 activity in the synovial fluid of older patients and that ADAMTS-4 activity in synovial fluid correlates with the level of effusion noted in the knee. The finding of no association with age in the present study is probably most readily explained by the smaller sample size. When exploring biomarker associations, we have shown that sCD14 levels are directly related to ADAMTS-4 activity in synovial fluid; this finding is not too surprising as CD14 positive macrophages are known to drive synovial ADAMTS-4 synthesis as part of the destructive and inflammatory responses characterized in OA. 5 We have endeavored to include as much patient demographic and injury information as available in our regression analyses because it is known that patient age, sex, BMI, and size and location of the defect can affect outcomes after ACI 4, 13 and may also affect biomarker levels in synovial fluid. However, it was not always possible to obtain all information for all patients, especially in a retrospective study such as this. For example, the presence of additional injuries that are likely to predispose to ACI failure was not always described at arthroscopic surgery; these might have included the presence of synovitis, meniscal tears, or the state of the subchondral bone. In addition, because our retrospective sample cohort only had matched data at both stages from 11 patients, it was not possible to accurately determine the effect of the stage 1 procedure on biomarker levels at stage 2. We acknowledge that this missing information is a limitation of the study. While studying biomarkers in synovial fluid can provide more information on the biology of degenerative joint disease than measuring their levels systemically, the ability to measure levels in blood plasma or serum is much more practical for widespread use in the clinic. Alternative methods for the detection of aggrecanase activity have shown promise for correlating levels in synovial fluid and blood, where aggrecan breakdown products are measured as opposed to ADAMTS-4 activity. 22, 23 We aim to evaluate these methodologies for our ACI patient cohort in future studies using preparations of blood serum and plasma.
To our knowledge, the study of biomarkers in synovial fluid and blood from patients treated for cartilage injuries is limited to 3 published studies, 27, 42, 45 only 2 of which have analyzed biomarkers in conjunction with outcomes after ACI treatment. Nganvongpanit et al 27 monitored serum levels of CS and HA in 10 dogs after ACI and drilling, with levels of CS in serum correlating negatively with the quality of repair. Vasara et al 42 followed 10 patients before ACI to 1 year after ACI, monitoring MMP3 and IGF-1, and saw higher levels of these at both time points compared with nontreated controls. The sample size in our study was larger in comparison but was still relatively small (54 patients), which limited the power of our analyses. The coefficient of determination (R 2 ) between predictors and outcomes would need to be at least 0.13 to be significant at the P = .05 level, assuming 80% power. This threshold could explain why our analysis failed to identify demographic variables, such as sex or BMI found to be predictive in a previous study that assessed aspects of cell quality in predicting the clinical outcomes of ACI using slightly more patients (n = 80). 30 The high detection limit of 2 assays (ADAMTS-4 and sCD14) prevented determining biomarker levels in all patients in our study. When the biomarker is the independent variable in a regression analysis, this poses no problem because a censored regression analysis can be used. 33 However, when the biomarker is a dependent variable, another approach is needed. Because sCD14 measurements were below the detection limit in only 1 sample, a simple and widely used imputation method (LDL/O2) could be used. 28 However, ADAMTS-4 activity was below the detection limit in 54 of 76 samples (71%). With such a large proportion of left-censored data, the simple imputation method would give biased results. 24, 28 Simply omitting all cases with missing data would be highly inefficient because it discards all information contained in the left-censored observations. 24, 28 The method that we chose (fitting a censored log-normal distribution to all biomarker values above the detection limit) has been found to provide unbiased estimates of the regression coefficients in comparative tests. 24, 28 This method performs best when the ADAMTS-4 data follow a censored lognormal distribution, and data from an earlier study in our center with 3 times as many samples above the detection limit found no evidence against the assumption of a log-normal distribution. 33 We therefore believe that the statistical methodology that we used to handle the left-censored data below the detection limit conforms to best current practice.
In summary, through this report, we have identified that ADAMTS-4 activity in synovial fluid shows promise as a predictive biomarker to improve ACI patient selection for cell therapy. We suggest that ADAMTS-4 activity levels in the synovial fluid of joints with cartilage defects may be used to help identify patients who will have a poorer outcome after conventional ACI treatment. Specifically, our results and analyses demonstrate that it is the absence of ADAMTS-4 activity preoperatively in synovial fluid that has the greatest value in predicting a positive response to ACI. In combination with other known predictors of ACI responses such as age, sex, BMI, and defect characteristics, the absence of detectable ADAMTS-4 in synovial fluid could be used when deciding the best treatment for cartilage defects. With that information, a treatment algorithm could be developed containing demographic risk factors and a panel of biomarker characteristics, which will help to inform the preclinical decision. In addition, ADAMTS-4 activity is in itself a likely therapeutic target for combined biological treatments. The concurrent administration of molecules that specifically inhibit aggrecanases 8, 9 with biological treatments may improve outcomes in patients with high levels of ADAMTS-4 activity in their joints, who would otherwise be less likely to benefit from standard ACI treatment.
